PARIS, Feb. 28, 2007 – HRA Pharma, a private pharmaceutical company focused on innovative treatments in women’s health and endocrinology, announced today that it has invested a further €2.5 M in its subsidiary Celogos. The funds will allow the French biotech company, a pioneer in the development of cell-based therapies for muscle disorders, to ramp up the on-going clinical development of its pipeline.
